Another novel Coronavirus vaccine has entered the clinical trial stage in China.
A coVID-19 recombinant protein vaccine developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongoma Biopharmaceutical Co., Ltd. has been approved for phase I clinical trials.
Recombinant protein vaccine is produced by expressing purified pathogen antigen protein in engineered cells through genetic engineering.
This novel coronavirus vaccine is different from the adenovirus vector vaccine and inactivated vaccine approved for clinical trial.
The vaccine was developed by Gao Fu and Yan Jinghua from the Institute of Microbiology at the Chinese Academy of Sciences.
It is reported that preclinical rhesus monkey challenge protection test results showed that the vaccine immunity can induce high levels of neutralizing antibodies, has an obvious protective effect.
The current phase I clinical trial will focus on testing the vaccine’s tolerance and safety in humans.
The vaccine team said it could be industrially produced with engineered cell lines and would be highly accessible.
There is still a long way to go from human clinical trials to the eventual use of a vaccine, and a long way to go.
The Institute of Microbiology of the Chinese Academy of Sciences has long been committed to the molecular epidemiology of emerging infectious diseases, the cross-species transmission of zoonotic viruses and the basic research on the structural biology of pathogens, and has accumulated many years of research in the field of coronavirus.